Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPE-791 for idiopathic pulmonary fibrosis
2025-521901-42-00Phase 2Authorised
- Sponsor
- Contineum Therapeutics
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 27
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing PIPE-791 with Placebo to PIPE-791 (2 arms). Primary endpoint: Change in forced vital capacity from baseline to Week 26. Planned start Sep 2026; status: authorised.
02
Drugs
PIPE-791
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2025-521901-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521901-42-00.